Fresh analysis indicates that individuals who discontinue new weight-loss injections like Wegovy and Mounjaro can put back on shed pounds much more quickly than those who stop traditional lifestyle plans.
Findings released in a major medical journal shows that while overweight individuals often shed substantial amounts of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month after stopping.
"Individuals using these drugs need to be aware of the risk of rapid rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery means a reversion to original mass in about one and a half years.
Comparing Approaches
The study, which reviewed dozens of studies involving thousands of participants, compared the results of GLP-1 agonists with conventional dieting.
Researchers point out that people who shed pounds through diet and exercise typically have a slower weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Fast Regain
Nutrition scientists believe the mode of action of the injections explains the amplified weight return.
These medications copy a natural hormone called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement results in hunger is no longer kept in check, making overeating much more probable."
A Lifelong Condition?
Medical guidelines recommend the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, due to the likelihood of relapse, the therapy should be considered long-term.
This opinion is reinforced by pharmaceutical companies, who say that the results "emphasize the persistent nature of obesity," similar to managing diseases like hypertension.
Patient Accounts
Users who have discontinued the jabs describe a intense return of cravings.
"I experienced something that goes on and I was suddenly ravenous," said a patient.
This difficulty is worsened if patients have not established permanent dietary or behavioural changes during therapy.
Significant Use
Survey data indicate that a significant number of adults in the UK have used these injections in the last 12 months, with desire being substantial.
- Adoption is higher among women than men.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while the jabs are powerful tools for shedding pounds, they are not a permanent solution and maintained weight loss hinges on integrated behavioural management.
